Fidelity Advisor Biotechnology Fund Class A (FBTAX) Fund Overview
Fidelity Advisor Biotechnology Fund Class A (FBTAX) — price $45.89 (-0.02%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Fidelity Advisor Biotechnology Fund Class A · FBTAX
Fidelity Advisor Biotechnology Fund Class A (FBTAX) is a non-diversified fund focused on capital appreciation through investments in biotechnology companies. The fund primarily invests in common stocks of companies engaged in the research, development, and distribution of biotechnological products and services.
Price as of Oct 2, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $45.89 |
| Change on the day | -0.02% |
| Price / earnings (trailing) | 12.57 |
Price & events
Watch the FBTAX film — every key number, told as a short cinematic story
~2 min · open the film
What is Fidelity Advisor Biotechnology Fund Class A (FBTAX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Fidelity Advisor Biotechnology Fund Class A (FBTAX) is the company analyzed here. In Q4 FY2023 it reported revenue of $149M and net income of $22M.
What do the latest results show for Fidelity Advisor Biotechnology Fund Class A (FBTAX)?
Short answer · as of
The most recent reported quarter, Q4 FY2023, carried revenue of $149M.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2023 | $149M | $22M | $1.57 (diluted) |
What are the financial strengths and risks for Fidelity Advisor Biotechnology Fund Class A (FBTAX)?
Short answer · as of
The distress and quality screens read Altman Z 12.58 · Piotroski F 8. Trailing ratios: ROE 42.5% · ROA 19.4% · current ratio 1.53 · free-cash-flow yield 2.1%.
Fidelity Advisor Biotechnology Fund Class A Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the FBTAX research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
How does Fidelity Advisor Biotechnology Fund Class A generate revenue?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) generates revenue primarily through management fees, which are charged as a percentage of the fund's assets under management (AUM). These fees compensate Fidelity for its expertise in selecting and managing the fund's investments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (9 figures)
The 9 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 7 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $45.89 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T09:34:57.731Z. | |
px.change | Change on the day | -0.02% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.009998 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 12.57 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2023 | $149M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2023 | $22M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 1 quarters through Q4 FY2023 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 12.58 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 42.5% · ROA 19.4% · current ratio 1.53 · free-cash-flow yield 2.1% | UNRECORDED | Stored key metrics — Captured 2026-10-02 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.